These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical significance of LATS and TSH in the blood. Lemarchand-Béraud T; Griessen M; Scazziga BR Ann Clin Res; 1972 Jun; 4(3):121-37. PubMed ID: 4625026 [No Abstract] [Full Text] [Related]
25. Isoelectric focusing of long-acting thyroid stimulator immunoglobulin G. Lonergan C; Babiarz D; Burke G J Clin Endocrinol Metab; 1973 Mar; 36(3):439-44. PubMed ID: 4631063 [No Abstract] [Full Text] [Related]
27. [Incidence of L.A.T.S. demonstration in untreated recent hyperthyroidism. Comparison of 2 continuous series]. Mornex R; Massin JP; Orgiazzi J; Savoie JC Ann Endocrinol (Paris); 1972; 33(2):177-84. PubMed ID: 4678455 [No Abstract] [Full Text] [Related]
28. The pathogenesis of thyrotoxicosis the discovery of LATS. Adams DD N Z Med J; 1975 Jan; 81(531):15-7. PubMed ID: 1055308 [No Abstract] [Full Text] [Related]
29. ["Long-acting thyroid stimulator" and thyrotropic hormone in thyrotoxicosis in newborn infants]. Gautier E; Juillard E; Lemarchand-Béraud T Schweiz Med Wochenschr; 1968 Jan; 98(1):8-12. PubMed ID: 5695264 [No Abstract] [Full Text] [Related]
31. The distribution of the long-acting thyroid stimulator among gamma G-immunoglobulins. Smith BR; Munro DS; Dorrington KJ Biochim Biophys Acta; 1969 Aug; 188(1):89-100. PubMed ID: 5820688 [No Abstract] [Full Text] [Related]
32. [Long-acting thyroid stimulator (LATS) in thyroid gland diseases and its relationship to the thyroid gland antibodies]. Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W Schweiz Med Wochenschr; 1967 Jul; 97(28):898-904. PubMed ID: 5587446 [No Abstract] [Full Text] [Related]
33. Experimental production of long-acting stimulator in vivo. Burke G J Lab Clin Med; 1968 Jul; 72(1):17-27. PubMed ID: 4968981 [No Abstract] [Full Text] [Related]
34. The interaction between thyroid tissue and the long-acting thyroid stimulator. Kendall-Taylor P; Smith BR; Munro DS Q J Med; 1971 Oct; 40(160):564-5. PubMed ID: 4110160 [No Abstract] [Full Text] [Related]
35. CLINICAL STUDIES ON THE LONG-ACTING THYROID STIMULATOR. NOGUCHI A; KURIHARA H; SATO S J Clin Endocrinol Metab; 1964 Feb; 24():160-5. PubMed ID: 14123839 [No Abstract] [Full Text] [Related]
36. Inactivation of long-acting thyroid stimulator in vivo. Smith BR; Munro DS J Endocrinol; 1972 Jan; 52(1):189-96. PubMed ID: 5061150 [No Abstract] [Full Text] [Related]
37. A modified bioassay for the long-acting thyroid stimulator (LATS). Furth ED; Rathbun M; Posillico J Endocrinology; 1969 Sep; 85(3):592-3. PubMed ID: 5793040 [No Abstract] [Full Text] [Related]
38. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS). Chopra IJ; Solomon DH; Limberg NP J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701 [No Abstract] [Full Text] [Related]
39. Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland. Adams DD; Kennedy TH J Clin Endocrinol Metab; 1967 Feb; 27(2):173-7. PubMed ID: 4163610 [No Abstract] [Full Text] [Related]
40. [Para-neoplastic hyperthyroidism with elevated plasmatic T.S.H]. Codaccioni JL; Jaquet P Ann Endocrinol (Paris); 1971; 52(4):553-6. PubMed ID: 5139434 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]